Personalis (NASDAQ:PSNL) Upgraded to Hold at Wall Street Zen

Personalis (NASDAQ:PSNL) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Other analysts have also issued research reports about the stock. BTIG Research set a $6.00 target price on shares of Personalis in a report on Wednesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $8.50 price target on shares of Personalis in a report on Monday, September 8th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Personalis presently has a consensus rating of “Buy” and an average price target of $7.42.

Personalis Stock Performance

PSNL opened at $6.10 on Friday. The company has a fifty day moving average price of $5.41 and a two-hundred day moving average price of $4.92. Personalis has a 52 week low of $2.83 and a 52 week high of $7.79. The firm has a market capitalization of $540.95 million, a PE ratio of -4.77 and a beta of 1.76.

Personalis (NASDAQ:PSNL) last released its earnings results on Tuesday, August 5th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. The firm had revenue of $17.20 million during the quarter, compared to analyst estimates of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts forecast that Personalis will post -1.4 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. American Century Companies Inc. raised its holdings in shares of Personalis by 33.9% in the 1st quarter. American Century Companies Inc. now owns 67,377 shares of the company’s stock valued at $236,000 after purchasing an additional 17,056 shares during the period. Trexquant Investment LP raised its holdings in shares of Personalis by 455.0% in the 1st quarter. Trexquant Investment LP now owns 122,959 shares of the company’s stock valued at $432,000 after purchasing an additional 100,804 shares during the period. Two Sigma Advisers LP raised its holdings in shares of Personalis by 25.6% in the 4th quarter. Two Sigma Advisers LP now owns 34,300 shares of the company’s stock valued at $198,000 after purchasing an additional 7,000 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Personalis by 53,126.7% in the 4th quarter. BNP Paribas Financial Markets now owns 71,856 shares of the company’s stock valued at $415,000 after purchasing an additional 71,721 shares during the period. Finally, XTX Topco Ltd raised its holdings in shares of Personalis by 147.0% in the 1st quarter. XTX Topco Ltd now owns 82,666 shares of the company’s stock valued at $290,000 after purchasing an additional 49,197 shares during the period. 61.91% of the stock is owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.